HOME >> BIOLOGY >> NEWS
Study shows drug blocks breast cancer migration to bone

An international research team has identified what may be a critical molecule in the ability of tumours to metastasize -- or spread -- into bone. The research, initiated at the University of Toronto and continued at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) in Vienna, found that a protein in bone called RANKL appears to communicate with a receptor in breast, prostate and skin cancer cells -- telling them to migrate. Moreover, a drug already known to block RANKL's activity may prevent cancers from spreading into the bone.

Roughly 120 years ago, scientists predicted that bone tissue might manufacture certain molecules that entice cancer cells to lodge there. More people die of metastases -- secondary tumours that develop elsewhere in the body -- than from their initial tumours and bone is particularly fertile "soil" for travelling cancer "seed" cells. It has been estimated that 70 per cent of patients with progressive breast cancer and 84 per cent of prostate cancer patients develop bone metastases.

D. Holstead Jones, a former post-doctoral fellow in Professor Josef Penninger's laboratory of medical biophysics and immunology at U of T, is the lead author of the paper, which appears in the March 30 issue of the journal Nature. The team also included researchers from the University of Western Ontario's Department of Physiology and Pharmacology. Josef Penninger is currently the director of the IMBA in Vienna, where the project is being continued.

Jones and her colleagues show that RANKL, a cytokine protein which is produced at high levels in bone marrow, acts on breast, prostate and skin cancer cells through the RANK receptor. Over the past few years, Penninger's lab had determined that RANKL is essential in both bone breakdown and in controlling the growth of cells that form a lactating mammary gland. Putting these two discoveries together, the team decided to study the link between breast cancer and bon
'"/>

Contact: Nicolle Wahl
nicolle.wahl@utoronto.ca
416-978-6974
University of Toronto
29-Mar-2006


Page: 1 2 3

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. Study finds gender differences in renal and other genes contributing to blood pressure
3. Study suggests estrogen deficiency can lead to obesity-induced high blood pressure after menopause
4. Study: Sticking to the sand might not be such good, clean fun for beachgoers
5. Study points to new way to predict death risk from torn aorta
6. Study identifies new gene therapy tools for inherited blindness
7. Study finds contaminated water reaching Floridas offshore keys
8. Study sheds light on why humans walk on two legs
9. Study explains how pathogens evolve to escape detection
10. Study finds hereditary link to premenstrual depression
11. Study identifies energy efficiency as reason for evolution of upright walking

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/1/2020)... ... July 01, 2020 , ... ... completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in the ... clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide customers ...
(Date:6/25/2020)... ... 24, 2020 , ... eClinical Solutions LLC , a ... accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ) on ... severe COVID-19. This is the first study of an XPO1 inhibitor in patients ...
(Date:6/23/2020)... ... June 23, 2020 , ... Rigaku Corporation , a ... in a series of TOPIQ webinars, which will cover the Transferable Aspherical Atom ... in response to social distancing measures that resulted in postponements and cancelations of ...
Breaking Biology News(10 mins):
(Date:6/11/2020)... ... June 09, 2020 , ... ... the NEON Micro-Tracer Solution, a highly accurate, contact tracing solution for ... the workplace. Contact tracing, a core disease control measure, is a key strategy ...
(Date:5/30/2020)... ... May 29, 2020 , ... ... device, diagnostics, and animal health markets, has enabled Cytovale, Inc., a medical technology ... and machine learning, to achieve their first patient in (FPI) in just seven ...
(Date:5/26/2020)... ... , ... Brilliant , the leading smart home control and lighting company, ... a new integration to bring more convenience, simplicity, and security to the smart home ... can now be controlled from Brilliant’s in-wall touchscreen control panels and mobile app. ...
(Date:5/21/2020)... ... May 20, 2020 , ... Exo (pronounced “Echo”) ... the company’s executive vice president of product engineering and report directly to CEO ... imaging space, bringing more than 24 years of technology leadership experience from Google, ...
Breaking Biology Technology:
Cached News: